DrugPatentWatch Database Preview

Details for Patent: 10,058,554

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 10,058,554 protect, and when does it expire?

Patent 10,058,554 protects PERSERIS KIT and is included in one NDA.

This patent has twenty patent family members in thirteen countries.

Summary for Patent: 10,058,554

Title:	Sustained release small molecule drug formulation
Abstract:	An injectable depot formulation includes a biocompatible polymer, an organic solvent combined with the biocompatible polymer to form a viscous gel, and a small molecule drug incorporated in the viscous gel such that the formulation exhibits an in vivo release profile having C.sub.max to C.sub.min ratio less than 200 and lag time less than 0.2.
Inventor(s):	Luk; Andrew S. (Castro Valley, CA), Junnarkar; Gunjan H. (Palo Alto, CA), Chen; Guohua (Sunnyvale, CA)
Assignee:	Indivior UK Limited (Slough, Berkshire, GB)
Application Number:	15/422,626
Patent Claim Types: see list of patent claims	Use; Formulation;

Drugs Protected by US Patent 10,058,554

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Indivior Inc	PERSERIS KIT	risperidone	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	210655-001	Jul 27, 2018		RX	Yes	No						ADMINISTRATION OF RISPERIDONE
Indivior Inc	PERSERIS KIT	risperidone	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	210655-002	Jul 27, 2018		RX	Yes	Yes						ADMINISTRATION OF RISPERIDONE

International Family Members for US Patent 10,058,554

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	056554
Austria	551989
Australia	2006299657
Canada	2624088